The good life.


Our merger with Aceragen is a key development in our goal to help patients with rare diseases get more from life.

Learn More

Idera’s merger with Aceragen means a focus on bringing novel therapies to patients with pulmonology and rheumatology diseases that typically have no available treatment.

Learn More


Idera’s TLR9 agonist may have potential to improve outcomes when used in combination with checkpoint inhibitors and other immune activators.

Learn More

The Latest

Keep up with what’s happening at Idera Pharmaceuticals.


Idera Pharmaceuticals Announces Name Change to Aceragen, Inc. and Provides Near-Term Strategic Outlook

Company completes preferred stock conversion, implements reverse stock split, and regains Nasdaq… Read more 

Idera Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

EXTON, Pa. and DURHAM, N.C. , Nov. 14, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc.… Read more 

Idera Pharmaceuticals Acquires Aceragen

Acquisition includes late-stage rare disease portfolio with anticipated 2023 clinical milestones… Read more 

Learn More